Medicilon once again won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023 based on its comprehensive strength.
The "Most Influential List of China's Pharmaceutical Industry" by the All-China Federation of Industry and Commerce (ACFIC), Pharmaceutical Chamber of Commerce has become one of the authoritative lists of Chinese pharmaceutical industry. The ACFIC invited first-class Chinese experts to form a selection team. The selection adheres to the principles of open collection, objective data, strict screening, and fair selection. United with a number of well-known Chinese media, focusing on the comprehensive capabilities of participating companies in terms of R&D professional capabilities, integrated service capabilities, professional R&D talent teams and quality assurance system, and good reputation, the 2022-2023 annual list of the most influential series in the pharmaceutical industry will be finally selected.
Medicilon is a professional pharmaceutical integrated R&D service contract research organization (CRO), providing a full range of one-stop new drug R&D services, in compliance with Chinese and international filing standards, to pharmaceutical companies and research institutions around the world. Our services cover the entire process of preclinical new drug research, including drug discovery, pharmacology research and preclinical research.
20 Years of Excellence
385+ IND Approved by FDA, NMPA, EMA, and TGA
2000+ Active Clients Worldwide
3100+ Scientists & Research Staff
84,600+ m2 Lab Space
At Medicilon, we are dedicated to help our clients develop their research and discovery programs from initial idea all the way through the IND filing phase. Our services span across medicinal chemistry, biology, API, CMC, formulation, and preclinical studies. We provide flexible business models, including stand-alone Fee for Services (FFS) and fully integrated FTE services. In addition, our facilities are GLP/GMP compliant, US-FDA, China NMPA and AAALAC accredited. All study reports can be presented in SEND format, supporting dual filing of IND applications in the US, EU, and China.